Loading
A phase 3 trial of atezolizumab, bevacizumab (glioblastoma use), fluorouracil (5-FU) and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by National Cancer Institute (NCI), active but no longer recruiting.
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study is a phase 3, randomised interventional study registered as NCT02997228 by National Cancer Institute (NCI), with a registry enrolment figure of 120 participants, started 2018-01-19 and due to reach its primary completion in 2027-06-01. Interventions recorded: Atezolizumab; Bevacizumab; Biospecimen Collection; Computed Tomography; Fluorouracil; Leucovorin; Magnetic Resonance Imaging; Oxaliplatin; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration. Conditions listed: Metastatic Colorectal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v7. Primary outcome: Progression free survival (PFS). Colorectal eligibility wording from the registry: "* Diagnosis of metastatic adenocarcinoma of colon or rectum without previous chemotherapy or any other systemic therapy for metastatic colorectal cancer except for one cycle of FOLFOX or capecitabine and oxaliplatin (CAPOX), either with or without bevacizumab prior to enrollment". Sites: United States. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bevacizumab (glioblastoma use), Atezolizumab, FOLFOX (5-FU, leucovorin, oxaliplatin), Fluorouracil (5-FU) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Fluorouracil (5-FU), Platinum agents and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Fluorouracil (5-FU), Platinum agents and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Fluorouracil (5-FU), Platinum agents and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/